- In January 2020, Abbvie had a clinical trial in the works with the chemical Elagolix, which is being tested for safety and efficacy in women with polycystic ovary syndrome. The business is now conducting a Phase 2 multicenter, double-blind, randomised, placebo-controlled research to evaluate Elagolix's safety and efficacy in women with polycystic ovarian syndrome (PCOS).
- In Jan 2020, Evotec SE and Bayer AG launched a new five-year multi-target collaboration with Celmatix Inc. to develop various clinical candidates for the treatment of polycystic ovarian syndrome, which is projected to drive the market during the forecast period.
Frequently Asked Questions
The market is segmented based on Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Segmentation, By Drugs (Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants, Anti-Obesity), Surgery (Wedge Resection, Laparoscopic Drilling), End User (Hospital, Ambulatory Surgical Centers, Others) – Industry Trends and Forecast to 2031.
.
The Global Polycystic Ovarian Syndrome Pcos Treatment Market size was valued at USD 6.16 USD Billion in 2023.
The Global Polycystic Ovarian Syndrome Pcos Treatment Market is projected to grow at a CAGR of 6% during the forecast period of 2024 to 2031.
The major players operating in the market include Bayer AG, Allergan, Merck & Co., Pfizer , Amgen, Agile Therapeutics, Ferring B.V, Addex Therapeutics, Mylan N.V., Lupin, Blairex Laboratories , Apothecus Pharmaceutical Corp, Eli Lilly And Company, Novartis AG, BIOCAD Global, Teva Pharmaceutical Industries , Johnson & Johnson Services ,.
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa.
